Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammopharmacology

06-04-2024 | Atopic Dermatitis | Review

Atopic dermatitis: treatment and innovations in immunotherapy

Authors: Francesco Ferrara, Andrea Zovi, Maurizio Capuozzo, Roberto Langella

Published in: Inflammopharmacology

Login to get access

Abstract

Atopic dermatitis (AD) is a common inflammatory skin disease characterized by itching and skin barrier dysfunction. Moderate to severe AD is often refractory to first-line topical treatments, and systemic immunosuppressants have been shown to be effective but have significant adverse effects. The paucity of basic treatments has contributed to the development of targeted topical and systemic immunotherapies based on the use of small molecules and biologic drugs which can directly interact with AD pathogenetic pathways. They represent a new era of therapeutic innovation. Additional new treatments are desirable since AD is a heterogeneous disease marked by different immunological phenotypes. This manuscript will review the mechanism of action, safety profile, and efficacy of promising new systemic immunological treatments for AD. Since moderate to severe AD can result in poor quality of life, the development of targeted and well-tolerated immunomodulators is a crucial purpose. The introduction of new pharmacological agents may offer new therapeutic options. However, there is the need to evaluate how "narrow-acting" agents, such as individual interleukin inhibitors, will perform under the safety and efficacy profiles compared with "broad-acting" agents, such as JAK inhibitors.
Literature
Bauman JN, Doran AC, King-Ahmad A, Sharma R, Walker GS, Lin J et al (2022) The pharmacokinetics, metabolism, and clearance mechanisms of abrocitinib, a selective Janus kinase inhibitor, in humans. Drug Metab Dispos 50:1106–1118PubMedCrossRef
Beck LA, Thaçi D, Deleuran M, Blauvelt A, Bissonnette R, de Bruin-Weller M et al (2020) Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol 21:567–577PubMedPubMedCentralCrossRef
Bissonnette R, Pavel AB, Diaz A, Werth JL, Zang C, Vranic I et al (2019) Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial. J Allergy Clin Immunol 144:1274–1289PubMedCrossRef
Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D et al (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389:2287–2303PubMedCrossRef
Blauvelt A, Langley RG, Lacour JP, Toth D, Laquer V, Beissert S et al (2022) Long-term 2 year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol 87:815–824PubMedCrossRef
Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B et al (2021) Dupilumab provides favourable long-term safety and efficacy in children aged ≥6 to <12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol 184:857–870PubMedCrossRef
Czarnowicki T, He H, Krueger JG, Guttman-Yassky E (2019) Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol 143:1–11PubMedCrossRef
de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, Zhang Q et al (2018) Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol 178:1083–1101PubMedCrossRef
Duhen R, Ballesteros-Merino C, Frye AK, Tran E, Shu-Ching Chang T, Koguchi Y et al (2021) Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. Nat Commun 12:1047PubMedPubMedCentralCrossRef
Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfeld C et al (2019) Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol 155:1371–1379PubMedPubMedCentralCrossRef
Gutermuth J, Pink AE, Worm M, Soldbro L, Bjerregård Øland C, Weidinger S et al (2022) Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol 186:440–452PubMedCrossRef
Guttman-Yassky E, Pavel AB, Zhou L, Estrada YD, Zhang N, Xu H et al (2019a) GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol 144:482-93e7PubMedCrossRef
Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R et al (2019b) Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 80:913-21e9PubMedCrossRef
Guttman-Yassky E, Blauvelt A, Eichenfeld LF, Paller AS, Armstrong AW, Drew J et al (2020a) Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b Randomized Clinical Trial. JAMA Dermatol 156:411–420PubMedPubMedCentralCrossRef
Guttman-Yassky E, Thaçi D, Pangan AL, Hong HC, Paap KA, Reich A et al (2020b) Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol 2020(145):877–884CrossRef
Licata G, Gambardella A, Tancredi V, Calabrese G, De Rosa A, Alfano R et al (2022) Face atopic dermatitis resistant to dupilumab: a case series of three patients successfully treated with upadacitinib. J Eur Acad Dermatol Venereol 36:e150–e152PubMedCrossRef
Mogul A, Corsi K, McAuliffe L (2019) Baricitinib: the second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 53:947–953PubMedCrossRef
Nemoto O, Furue M, Nakagawa H, Shiramoto M, Hanada R, Matsuki S et al (2016) The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo- controlled study. Br J Dermatol 174:296–304PubMedCrossRef
Paller AS, Wollenberg A, Siegfried E, Thaçi D, Cork MJ, Arkwright PD et al (2021) Laboratory Safety of dupilumab in patients aged 6–11 years with severe atopic dermatitis: results from a phase iii clinical trial. Paediatr Drugs 23:515–527PubMedPubMedCentralCrossRef
Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Freidman M et al (2018) In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol 2:23PubMedPubMedCentralCrossRef
Patruno C, Fabbrocini G, Longo G, Argenziano G, Ferrucci SM, Stingeni L et al (2021a) Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study. Am J Clin Dermatol 22:581–586PubMedCrossRef
Patruno C, Napolitano M, Argenziano G, Peris K, Ortoncelli M, Girolomoni G et al (2021b) DADE-Dupilumab for Atopic Dermatitis of the Elderly study group. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol 35:958–964PubMedCrossRef
Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K et al (2021) Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 397:2169–2181PubMedCrossRef
Ruzicka T, Hanifn JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, XCIMAStudyGroup et al (2017) Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med 376:826–835PubMedCrossRef
Seegräber M, Srour J, Walter A, Knop M, Wollenberg A (2018) Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol 11:467–474PubMedCrossRef
Silverberg JI, Kantor R (2017) The role of interleukins 4 and/or 13 in the pathophysiology and treatment of atopic dermatitis. Dermatol Clin 35:327–334PubMedCrossRef
Silverberg JI, Pinter A, Pulka G, Poulin Y, Bouaziz JD, Wollenberg A et al (2019) Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol 145:173–182PubMedCrossRef
Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, ECZTRA3studyinvestigators et al (2021) Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol 184:450–463PubMedPubMedCentralCrossRef
Silverberg JI, Rubini NPM, Pires MC, Rossi AB, Zhang A, Chen Z et al (2022) Dupilumab treatment reduces hospitalizations in adults with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract 10:1279–85.e1PubMedCrossRef
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, SOLO1andSOLO2Investigators et al (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 375:2335–2348PubMedCrossRef
Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taieb A et al (2018) Efficacy and safety of lebrikizumab (an antiIL-13 monoclonal antibody) in adults with moderate- to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol 78:863-71e11PubMedCrossRef
Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ et al (2020) Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol 156:44–56PubMedCrossRef
Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N et al (2022) Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol 158:404–413PubMedPubMedCentralCrossRef
Suarez-Farinas M, Ungar B, da Rosa CJ, Ewald DA, Rozenblit M, Gonzalez J et al (2015) RNA sequencing atopic dermatitis transcriptome profling provides insights into novel disease mechanisms with potential therapeutic implications. J Allergy Clin Immunol 135:1218–1227PubMedCrossRef
Uchida H, Kamata M, Mizukawa I, Watanabe A, Agematsu A, Nagata M et al (2019) Real- world efectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study. Br J Dermatol 181:1083–1085PubMedCrossRef
Wang C, Kraus CN, Patel KG, Ganesan AK, Grando SA (2020) Realworld experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients records. Int J Dermatol 59:253–256PubMedCrossRef
Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K et al (2019) Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol 143:135–141PubMedCrossRef
Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, ECZTRA 1 and ECZTRA 2 study investigators et al (2021) Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 184:437–449PubMedCrossRef
Worm M, Simpson EL, Thaçi D, Bissonnette R, Lacour JP, Beissert S et al (2020) Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol 156:131–143PubMedCrossRef
Metadata
Title
Atopic dermatitis: treatment and innovations in immunotherapy
Authors
Francesco Ferrara
Andrea Zovi
Maurizio Capuozzo
Roberto Langella
Publication date
06-04-2024
Publisher
Springer International Publishing
Published in
Inflammopharmacology
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-024-01453-8